Organon & Co. is a health care company that develops and delivers health solutions through a diverse portfolio of prescription therapies. Its primary revenue comes from women's health products (approximately 30%), biosimilars (20%), cardiovascular medications (25%), respiratory treatments (10%), and dermatology and other health products (15%). The company serves various customers, including drug wholesalers, retailers, hospitals, government agencies, and managed health care providers. Factors supporting endurance include a broad product portfolio and established relationships with healthcare providers, while potential limitations include competition from generic drugs and regulatory challenges in the pharmaceutical industry.
—
Organon & Co. is a health care company that develops and delivers health solutions through a diverse portfolio of prescription therapies. Its primary revenue comes from women's health products (approximately 30%), biosimilars (20%), cardiovascular medications (25%), respiratory treatments (10%), and dermatology and other health products (15%). The company serves various customers, including drug wholesalers, retailers, hospitals, government agencies, and managed health care providers. Factors supporting endurance include a broad product portfolio and established relationships with healthcare providers, while potential limitations include competition from generic drugs and regulatory challenges in the pharmaceutical industry.
—
Daily adjusted close
Organon & Co. is a health care company that develops and delivers health solutions through a diverse portfolio of prescription therapies. Its primary revenue comes from women's health products (approximately 30%), biosimilars (20%), cardiovascular medications (25%), respiratory treatments (10%), and dermatology and other health products (15%). The company serves various customers, including drug wholesalers, retailers, hospitals, government agencies, and managed health care providers. Factors supporting endurance include a broad product portfolio and established relationships with healthcare providers, while potential limitations include competition from generic drugs and regulatory challenges in the pharmaceutical industry.